Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6

Clinical Science

Volumn 92, Issue 2, 1997, Pages 215-221

  Wigmore, Stephen J ^a   Fearon, Kenneth C H ^a   Maingay, Jean P ^a   Ross, James A ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Acute phase response; Cachexia; Eicosapentaenoic acid; Interleukin 6

Indexed keywords

C REACTIVE PROTEIN; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NEUTRALIZING ANTIBODY;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; BLOOD LEVEL; CACHEXIA; CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIVER CELL; MALE; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; WEIGHT REDUCTION;

EID: 0031035334     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0920215     Document Type: Article

References (24)

1. Falconer JS, Fearon KCH, Plester CE, et al. Cytokines, the acute phase response and energy expenditure in weight-losing patients with pancreatic cancer. Ann Surg 1994; 219: 325-31
2. Falconer JS, Fearon KCH, Ross JA, et al. The acute phase response, weight loss and survival duration in pancreatic cancer. Cancer 1995; 75: 2077-82.
3. Castell JV, Gomez-Lechon MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-86.
4. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biologic coin. Nature (London) 1986; 320: 584-8.
5. Sherry BA, Gelin J, Fong Y, et al. Anti-cachectin/tumour necrosis factor alpha antibodies attenuate the development of cachexia in tumour models. FASEB J 1989; 3: 1956-62.
6. Smith BA, Kluger MJ. Anti-TNFα antibodies normalised body temperature and enhanced food intake in tumour-bearing rats. Am J Physiol 1993; 265: 615-19.
7. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumour necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265-71.
8. Meydani SN, Endres S, Woods MM, et al. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 1991; 121: 547-55.
9. Meydani SN, Lichtenstein AH, Cornwall S, et al. Immunologic effects of national cholesterol education panel step-2 diets with and without fish-derived n-3 fatty acid enrichment. J Clin Invest 1993; 92: 105-13.
10. Wigmore SJ, Ross JA, Plester CE, et al. Effect of polyunsaturated fatty acids on cachexia in weight losing patients with pancreatic cancer. Nutrition 1996; 12 (Suppl.): 23-26.
11. Goldie AS, Fearon KCH, Ross JA, et al. Natural cytokine antagonists and endogenous anti-endotoxin core antibodies in sepsis syndrome. J Am Med Assoc 1995; 274: 172-7.
12. Lord E. The use of the range in place of the standard deviation in the t-test. Biometrika 1947; 34: 41.
13. O'Riordan MG, Ross JA, Fearon KCH, et al. Insulin and the counter-regulatory hormones influence acute phase protein production in the human hepatocyte. Am J Physiol 1995; 269: E323-30.
14. Falconer JS, Ross JA, Fearon KCH. A phase II study of gamma-linolenic acid in pancreatic cancer and its effect on immune function and cytokine production. In: Horrobin D, ed. New approaches to cancer treatment. Edinburgh: Churchill-Livingstone, 1994: 68-78.
15. Cheema SK, Clandinin MT. Diet fat alters expression of genes for enzymes of lipogenesis in lean and obese mice. Biochim Biophys Acta 1996; 1299: 284-8.
16. Wigmore SJ, Ross JA, Fearon KCH, et al. Human pancreatic cancer cells stimulate CRP production by hepatocytes via IL-6 or IL-8. Br J Surg 1994; 81: 1814.
17. Kishimoto T, Taga T. gp130 - common signal transducer for cytokines including IL-6. In: Proceedings of the 8th International Congress of Immunology. Springer-Verlag: New York, 1993: 887-91.
18. Wigmore SJ, Fearon KCH, Ross JA. Modulation of human hepatocyte acute phase protein production in vitro by n-3 and n-6 polyunsaturated fatty acids. Ann Surg 1996 (in press).
19. Falconer JS, Ross JA, Fearon KCH, et al. Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer 1994; 69: 826-32.
20. Tisdale MJ, Beck SA. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vitro by eicosapentaenoic acid. Biochem Pharmacol 1991; 41: 103-7.
21. Beck SA, Smith KL, Tisdale MJ. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 1991; 51: 6089-93.
22. Todorov P, Cariuk P, Mcdevitt T, et al. Characterisation of a cancer cachectic factor. Nature (London) 1996; 379: 739-42.
23. de Caterina R, Cybulsky MI, Clinton SK, et al. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arteriosclerosis Thromb 1994; 14: 1829-36.
24. Reeds PJ, Fjeld JR, Jahoor F. Do the differences between the amino acid composition of acute-phase and skeletal muscle proteins have a bearing on nitrogen loss in traumatic states? J Nutr 1994; 124: 906-10.